NICE received one appeal against the Final Appraisal Document on the Technology Appraisal for dapagliflozin for treating heart failure with reduced ejection fraction from the British Society for Heart Failure. The Vice Chair of NICE has since rejected the appeal, and therefore an appeal hearing will not be held.